## **Redefining Child Protection**

Obstetrics and Gynecology 140, 167-173

DOI: 10.1097/aog.0000000000004786

Citation Report

#	Article	IF	CITATIONS
1	Child-centred harm reduction. International Journal of Drug Policy, 2022, 109, 103857.	3.3	0
2	Envisioning Minimally Disruptive Opioid Use Disorder Care. Journal of General Internal Medicine, 2023, 38, 799-803.	2.6	7
3	Incidence of Newborn Drug Testing and Variations by Birthing Parent Race and Ethnicity Before and After Recreational Cannabis Legalization. JAMA Network Open, 2023, 6, e232058.	5.9	6
4	Assessing the clinical utility of toxicology testing in the peripartum period. American Journal of Obstetrics & Synecology MFM, 2023, 5, 100963.	2.6	2
5	Reducing the stigma of perinatal substance use disorders: the time is now. Archives of Women's Mental Health, 2023, 26, 411-413.	2.6	O
6	Women's experiences in injectable opioid agonist treatment programs in Vancouver, Canada. International Journal of Drug Policy, 2023, 117, 104054.	3.3	1
7	Principles of care for pregnant and parenting people with substance use disorder: the obstetrician gynecologist perspective. Frontiers in Pediatrics, $0,11,.$	1.9	2
8	Outcomes and experiences after child custody loss among mothers who use drugs: A mixed studies systematic review. Drug and Alcohol Dependence, 2023, 251, 110944.	3.2	2
9	Achieving Equity in Child and Adolescent Mental Health by Addressing Racism Through Prevention Science. Adversity and Resilience Science, 2024, 5, 1-10.	2.6	0
10	Reconsidering the Use of Urine Drug Testing in Reproductive Settings. American Journal of Obstetrics & amp; Gynecology MFM, 2023, , 101206.	2.6	O
11	Substance Use-Associated Infant Maltreatment Report Rates in the Context of Complex Prenatal Substance Use Policy Environments. Child Maltreatment, 0, , .	3.3	O